EMT is a cellular program whereby epithelial cells relinquish their tight junctions and intrinsic polarity to acquire mesenchymal traits—traits that endow cancer cells with increased motility, invasiveness, and resistance to apoptosis. This phenotypic plasticity is a fundamental driver of metastasis, yet targeting EMT therapeutically has been confounded by its intricate regulation and the transcription factors traditionally involved, many of which lack druggable features. Professor Wong’s team circumvented this obstacle by applying an innovative master regulator (MR) algorithm, capable of dissecting vast gene-protein interaction networks to reveal non-canonical regulatory molecules within cancer cells. Analyzing over 8,000 patient samples across 20 types of malignancies curated by The Cancer Genome Atlas (TCGA), they pinpointed DNM1 as a novel, non-transcriptional modulator orchestrating EMT dynamics.

Dynamin 1, historically studied for its canonical role in endocytosis, emerged in this study as a linchpin controlling the turnover and recycling of N-cadherin, a key adhesion molecule and hallmark of the mesenchymal phenotype. Elevated DNM1 expression correlated strongly with advanced disease stages and mesenchymal tumor subtypes, and, strikingly, higher DNM1 levels were prognostic of poorer survival outcomes. This inverse relationship between DNM1 expression and patient prognosis emphasizes the biological and clinical significance of its role, differentiating it from traditional EMT regulators and underscoring its potential as a biomarker and therapeutic target.

To experimentally substantiate these computational insights, the researchers examined the functional consequences of modulating DNM1 in various ovarian cancer cell lines. Suppression of DNM1 drastically diminished the cells’ migratory ability, simultaneously curtailing N-cadherin levels. Conversely, ectopic overexpression of DNM1 in non-metastatic cells induced a marked increase in invasiveness alongside elevated N-cadherin expression. This bidirectional manipulation elucidated the causative role of DNM1 in promoting a mesenchymal, motile phenotype crucial for metastasis. Complementary in vivo studies employing murine models further validated that reduced DNM1 expression suppressed intra-abdominal dissemination of ovarian cancer cells, reinforcing the protein’s centrality in metastatic progression.

Mechanistically, the study unveiled that DNM1 facilitates the endocytic recycling of glycosylated N-cadherin, a process vital for sustaining cell polarity and directed migration. Unlike transcription factors governing EMT gene expression, DNM1 operates at the post-translational level, manipulating protein trafficking pathways to maintain mesenchymal cellular states conducive to metastasis. By enhancing N-cadherin recycling, DNM1 preserves the plasticity and adaptability of cancer cells, enabling them to navigate complex microenvironments and breach biological barriers with heightened efficiency.

Complementary genomic approaches integrating ATAC-seq and RNA-seq illuminated a contrasting molecular signature in non-metastatic cells, which exhibited higher expression of B3GALT1, a glycosyltransferase implicated in inhibiting EMT progression. B3GALT1 appears to diminish N-cadherin recycling, thereby abrogating its surface expression and limiting metastatic competencies. This yin-yang interplay between DNM1 and B3GALT1 portrays a finely tuned regulatory balance influencing ovarian cancer’s metastatic trajectory and suggests that restoring B3GALT1 activity might be a viable strategy to restrain EMT and tumor dissemination.

Intriguingly, the investigation also revealed a serendipitous linkage between DNM1 expression and nanomedicine responsiveness. Metastatic ovarian cancer cells with elevated DNM1 were found to internalize nanoparticle-based therapeutics more efficiently, implying that DNM1’s role in endocytic pathways could be harnessed to augment targeted drug delivery. This insight elevates the DNM1-N-cadherin axis beyond a mere mechanistic curiosity, positioning it as a dual-purpose target with both anti-metastatic and drug delivery-enhancing potential.

Taken together, Professor Wong’s research delineates a novel molecular axis—DNM1-mediated endocytic recycling of N-cadherin—that sustains the mesenchymal phenotype fundamental to ovarian cancer metastasis. The identification of DNM1 as a master regulator operating through membrane trafficking, rather than transcriptional reprogramming, represents a paradigm shift for the field. This mechanism not only provides a fresh perspective on tumor biology but also charts a feasible path for therapeutic interventions aimed at halting or even reversing metastatic progression in ovarian cancer patients.

Beyond deepening biological understanding, these findings raise tantalizing prospects for clinical translation. Therapeutic strategies designed to inhibit DNM1 function could stymie cancer cell motility and dissemination, thereby improving patient outcomes. Moreover, the enhanced uptake of nanodrugs by DNM1-high metastatic cells suggests that nanotherapy platforms may be optimized or personalized based on DNM1 expression profiles, increasing drug efficacy while potentially reducing systemic toxicity. Such precision medicine approaches could radically transform the management of advanced ovarian cancer, a domain historically mired in therapeutic futility.

Further research exploring small-molecule inhibitors or biologics targeting DNM1, along with the development of diagnostic tools quantifying its expression, will be critical next steps. Additionally, investigating the interplay between DNM1, glycosylation enzymes like B3GALT1, and other endocytic regulators could unravel additional vulnerabilities exploitable for intervention. Understanding how DNM1’s activity integrates with the tumor microenvironment and standard chemotherapies will also be essential to effectively translate these findings into clinical practice.

In summary, the work from The University of Hong Kong heralds a new frontier in ovarian cancer research, revealing how a previously underappreciated protein governs the plasticity and metastatic propensity of tumor cells through a non-transcriptional mechanism. This advances the paradigm of cancer metastasis, shifting focus to the dynamic control of protein trafficking and receptor recycling as fertile ground for scientific exploration and drug development. It is a clarion call for heightened investigation into the molecular choreography that fuels cancer aggression, with hopes for more effective and durable treatments on the horizon.

Subject of Research: Cells

Article Title: Dynamin 1-mediated endocytic recycling of glycosylated N-cadherin sustains the plastic mesenchymal state to promote ovarian cancer metastasis

News Publication Date: 10-Apr-2025

Web References: http://dx.doi.org/10.1093/procel/pwaf019

Image Credits: The University of Hong Kong

Keywords: Health and medicine, Life sciences

Metastasis, the spread of cancer cells from primary tumors to distant organs, remains the deadliest aspect of breast cancer and a major therapeutic challenge. While genetic mutations have been extensively studied as drivers of metastasis, emerging evidence increasingly points to epigenetic and post-transcriptional regulatory layers. The current work emphasizes the underappreciated role of small nucleolar RNAs (snoRNAs), which historically were considered housekeeping molecules involved solely in ribosomal RNA modification. Snord67, a box C/D snoRNA, now emerges as a powerful orchestrator of RNA splicing alterations that fuel cancer dissemination.

At the heart of the splicing process lies the spliceosome, a dynamic ribonucleoprotein complex responsible for excising introns and ligating exons during pre-mRNA processing. A critical component of this machinery is U6 small nuclear RNA (snRNA), which undergoes various chemical modifications essential for spliceosomal function and fidelity. Snord67 directs 2′-O-methylation modifications on U6 snRNA, fine-tuning its structural conformation and interaction capabilities. This subtle yet crucial modification translates into broad, genome-wide changes in alternative splicing patterns observed in metastatic breast cancer cells.

The researchers employed a combination of CRISPR-based gene editing, high-throughput RNA sequencing, and splicing-sensitive reporter assays to dissect the function of Snord67 in breast cancer models. Loss-of-function experiments demonstrated that abrogating Snord67 expression dramatically reduced cell migration and invasion in vitro, as well as metastasis formation in murine xenograft models, highlighting its functional necessity. Conversely, overexpression of Snord67 enhanced metastatic traits, underscoring its oncogenic potential.

Delving deeper into the molecular consequences, the team mapped U6 snRNA modifications via sophisticated chemical probing methods, revealing that Snord67 specifically methylates conserved nucleotides within the catalytic core of U6. These epitranscriptomic changes modulate the spliceosome’s catalytic efficiency and specificity, leading to widespread alterations in exon inclusion or skipping across hundreds of genes. Many of the affected transcripts encode proteins involved in cell adhesion, cytoskeletal remodeling, and epithelial-to-mesenchymal transition (EMT), processes intrinsically linked to metastatic competence.

Strikingly, alternative splicing events orchestrated by Snord67-guided U6 modification do not merely represent passenger changes but actively reprogram cellular identity. The researchers identified splicing isoforms of key signaling molecules and adhesion receptors whose expression enhances motility and survival in the hostile microenvironment encountered during metastatic dissemination. This evidence collectively suggests Snord67 acts as a master regulator reshaping the transcriptome to favor cancer progression.

Beyond mechanistic insights, the study has important implications for therapeutic intervention. Targeting snoRNA-mediated modifications, a relatively unexplored therapeutic avenue, could allow precision modulation of splicing networks with high tumor specificity. The researchers propose that inhibitors designed to disrupt Snord67-guided methylation or its interaction with the spliceosome might impair metastatic capacity while sparing normal tissues. This represents an innovative angle in the battle against metastatic breast cancer, a disease stage notoriously resistant to existing treatments.

Moreover, the clinical relevance of Snord67 expression was supported by analyses of patient tumor datasets. Elevated levels of Snord67 were correlated with poor prognosis and higher incidence of metastasis across multiple breast cancer subtypes. This biomarker potential paves the way for developing prognostic assays and stratification tools to identify patients at greater risk of metastatic relapse, thus helping personalize treatment regimens to improve outcomes.

The study also prompts a reevaluation of the functions attributed to noncoding RNAs, particularly snoRNAs. Traditionally sidelined as “housekeeping,” these molecules are now revealed to be dynamic regulators embedded in oncogenic networks. Their ability to direct precise chemical RNA modifications underscores the epitranscriptomic complexity governing cancer cell biology. This adds a new dimension to the growing field of RNA-based regulation in health and disease.

Intriguingly, the therapeutic window for targeting snoRNAs or their guided modifications might extend beyond breast cancer, as similar epitranscriptomic alterations have been observed in other solid tumors and hematologic malignancies. This raises the exciting possibility of broad-spectrum anti-metastatic strategies grounded in correcting aberrant RNA chemical modifications.

The innovative methodologies leveraged in this work also highlight the power of integrative approaches combining genomic editing with state-of-the-art sequencing and chemical biology. Such multidisciplinary efforts are crucial to decrypting the multifaceted layers of RNA regulation that drive complex phenotypes like metastasis. The precise mapping of RNA modifications on individual spliceosomal components represents a technical tour de force advancing the frontier of RNA biology.

This discovery shines a spotlight on the intricate molecular choreography underpinning breast cancer metastasis, emphasizing how subtle chemical tweaks to RNA molecules can trigger large-scale transcriptomic rewiring. As we deepen our molecular understanding of cancer’s spread, research such as this will be instrumental in propelling the development of next-generation targeted therapies aimed at halting metastasis at its molecular roots.

In conclusion, the identification of Snord67 as a facilitator of breast cancer metastasis through its epitranscriptomic guidance of U6 snRNA methylation and ensuing splicing landscape remodeling offers a transformative perspective on cancer biology. It spotlights novel molecular vulnerabilities and opens new avenues for intervention against metastatic breast cancer, a pressing clinical challenge worldwide. This landmark study lays the foundation for future endeavors to translate these insights into tangible clinical advances, bridging the gap between molecular science and patient benefit.

Subject of Research: The role of Snord67 in breast cancer metastasis via U6 snRNA modification and alternative splicing modulation.

Article Title: Snord67 promotes breast cancer metastasis by guiding U6 modification and modulating the splicing landscape.

Article References:
Chao, Y.L., Zhou, K.I., Forbes, K.K. et al. Snord67 promotes breast cancer metastasis by guiding U6 modification and modulating the splicing landscape. Nat Commun 16, 4118 (2025). https://doi.org/10.1038/s41467-025-59406-w

Image Credits: AI Generated